SII’s multivalent meningococcal meningitis vaccine gets WHO prequalification
It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa
The Serum Institute of India (SII) on Wednesday said its vaccine to protect against the five predominant causes of meningococcal meningitis in Africa has been prequalified by the World Health Organisation (WHO), making the vaccine eligible to be procured by United Nations agencies and Gavi, the vaccine alliance.
The MenFive vaccine has been developed through a 13-year collaboration between the Serum institute and PATH, a global nonprofit, with funding from the UK government’s Foreign, Commonwealth and Development Office.
The prequalification by WHO, which ensures a vaccine meets strict international quality, safety, and efficacy standards, was supported by extensive clinical studies in The Gambia, India, and Mali.
Also Read: 12 African countries to get 18 million doses of first-ever malaria vaccine
Importantly, prequalification allows MenFive to be procured by United Nations agencies and Gavi.
“As the first conjugate vaccine to safeguard against the five predominant causes of this deadly disease, MenFive offers hope for a future free from annual outbreaks and epidemics in the African meningitis belt,” SII CEO Adar Poonawalla said in a statement.
The vaccine protects against meningococcal serogroups A, C, W, Y, and X and is designed to eliminate annual meningitis outbreaks and epidemics in the African meningitis belt -- a string of 26 countries from Senegal and The Gambia in the west to Ethiopia in the east.
It is also the only vaccine that prevents meningitis caused by meningococcal group X, a pathogen increasingly implicated in meningitis outbreaks in Africa.
